Do peptides really work for weight loss?

The phrase "weight loss peptides" actually covers several very different things:

• GLP-1 and related incretin drugs (for example, semaglutide, tirzepatide, retatrutide): regulated medicines with substantial clinical trial data.
• Experimental metabolic peptides such as AOD-9604 or 5-amino-1MQ: usually discussed in preclinical or small early-stage human studies.
• Combination products and "stacks" that mix multiple compounds, sometimes with limited formal evidence for the exact combination being used.

Asking whether "peptides work" is therefore too broad; the answer depends heavily on which molecule, what dose, and what evidence supports that use.

For clinically regulated products such as semaglutide or tirzepatide, the evidence is not vague — it comes with names, participant counts, and percentages:

• STEP 1 randomized 1,961 adults with overweight or obesity and no diabetes. Semaglutide 2.4 mg weekly produced a mean weight change of −14.9% versus −2.4% for placebo at 68 weeks (NEJM 2021).
• SURMOUNT-1 randomized 2,539 adults. Tirzepatide produced −20.9% at 15 mg and −15.0% at 5 mg versus −3.1% for placebo at 72 weeks; 57% of the 15 mg group lost at least a fifth of their body weight, versus 3% on placebo (NEJM 2022).
• SCALE, the older liraglutide trial, randomized 3,731 adults and produced a mean loss of 8.4 kg versus 2.8 kg on placebo over 56 weeks — the same drug class, a generation earlier, and a useful reminder that "GLP-1" is not one effect size (NEJM 2015).
• SELECT went beyond the scale: in 17,604 adults with cardiovascular disease and overweight or obesity but no diabetes, semaglutide cut first cardiovascular events to 6.5% versus 8.0% on placebo (HR 0.80, 95% CI 0.72–0.90) (NEJM 2023).

Key features of that evidence base include:

• Randomized, controlled trial designs with hundreds or thousands of participants.
• Defined dosing regimens and titration schedules.
• Follow-up over many months to assess both efficacy and safety.
• Formal monitoring of adverse events and contraindications.

These data support the idea that certain peptide-based drugs can play a powerful role in weight management when used as part of a medical treatment plan.

Many other peptides discussed in weight loss contexts—such as AOD-9604, 5-amino-1MQ, or unregulated combination vials—have a much thinner evidence base. Two concrete examples:

• AOD-9604, a fragment of human growth hormone, was in phase IIa obesity trials by February 2002 (Curr Opin Investig Drugs 2004). More than two decades later it has no approval and no published human efficacy results.
• 5-amino-1MQ — a methylquinolinium salt, not actually a peptide — belongs to a series of NNMT inhibitors that reduced body weight, white adipose mass and adipocyte size in diet-induced obese mice (Biochem Pharmacol 2018). No human trials have been published.

The pattern behind those examples generalizes:

• A larger share of the research is preclinical (animal or cell models).
• Human studies, when they exist, may be small, short, or focused on surrogate markers rather than long-term outcomes.
• Real-world protocols often do not match the doses and schedules used in published studies.

In these cases, it is more accurate to say that such peptides are hypothesis- generating tools rather than proven weight loss therapies.

Even with effective medicines, weight and metabolic health remain strongly influenced by:

• Nutrition and overall energy balance.
• Physical activity and resistance training.
• Sleep, stress, and other lifestyle factors.
• Co-existing conditions and other medications.

Peptide-based treatments are typically studied on top of background lifestyle advice, not as a replacement for it — every participant in STEP 1 received lifestyle counselling alongside the injection. Real-world responses vary significantly between individuals.

Duration matters as much as dose. In the STEP 1 off-treatment extension, 327 participants stopped the drug at week 68 and were followed for another year: the semaglutide group regained 11.6 percentage points of the weight they had lost — about two-thirds of it — ending at −5.6% from baseline versus −17.3% at week 68, with cardiometabolic markers reverting toward baseline as well (Diabetes Obes Metab 2022). These drugs treat obesity while they are taken; they do not cure it.

When evaluating bold marketing claims about weight loss peptides, it can help to ask:

• What human data exist? Are there randomized trials, or mostly anecdotes and preclinical papers?
• What endpoints were measured? Weight change, metabolic markers, or only surrogate lab findings?
• How long were people followed? Short-term changes may not reflect long-term maintenance or safety.
• How similar is the real-world protocol (dose, frequency, route) to what is described in the literature?

A cautious, evidence-aware mindset helps avoid over-interpreting early or limited data.

For a broader view of this topic, you may find these pages helpful:

• What are weight loss peptides?
• What is the safest peptide for weight loss?
• Semaglutide vs research peptides for weight loss

You can also explore the structural catalog entries for commonly discussed compounds:

• Semaglutide
• Tirzepatide
• Retatrutide
• AOD-9604
• 5-amino-1MQ